In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eurand

This article was originally published in The Tan Sheet

Executive Summary

Drug delivery firm acquired by investment firm E.M. Warburg, Pincus from American Home Products, Eurand says April 15. OTC products made by Eurand include enhanced delivery acetaminophen products as well as taste-masked pseudoephedrine, dextromethorphan and diphenhydramine syrups and soft melt tablets. The firm also has developed an enhanced delivery ranitidine product that is not yet sold in the U.S.; the launch may begin in about 18 months. Warner-Lambert markets OTC Zantac 75 ranitidine stomach acid blocker; private label ranitidine is expected to reach the market June 19. AHP acquired Eurand as part of its acquisition of A.H. Robins in 1989. Warburg, Pincus has holdings in several Rx drug and device firms

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS089677

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel